3SBio, Inc.: Exhibit 4.21 - Filed by newsfilecorp.com











Exhibit 4.21 


AMENDMENT  TO EQUITY PLEDGE AGREEMENT 


   Amendment No. 1 dated as of December 31, 2012 (this “Amendment”) to the EQUITY PLEDGE AGREEMENT, entered into on January 1, 2007 (the “Agreement”), between Shenyang Sunshine Pharmaceutical
Company Limited, a PRC company (the “Company”), and Mr. Dan LOU (the “Nominee”). Capitalized terms used herein and not defined shall have the meanings specified in the Agreement.  


     WHEREAS, the Company and the Nominee are parties to the Agreement; 


     NOW, THEREFORE, in consideration of the promises and mutual agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Company
and the Nominee hereby agree as follows:      


     A. Amendment.  


(i) Article 4.2 of the Agreement is hereby amended and restated in its entirety to read as follows: 


"Pledgee is entitled to collect all dividends and other distributions on the Equity, if and when declared and paid by Liaoning Sunshine,
during the term of this Agreement." 


     B. Effect of Amendment. Except as expressly set forth herein, the Agreement shall not by implication or otherwise be supplemented or amended by virtue of this Amendment, but shall remain in full force and effect, as amended hereby. This
Amendment shall be construed in accordance with and as a part of the Agreement, and all terms, conditions, representations, warranties, covenants and agreements set forth in the Agreement and each other instrument or agreement referred to therein,
except as herein amended, are hereby ratified and confirmed. To the extent that there is a conflict between the terms and provisions of the Agreement and this Amendment, the terms and provisions of this Amendment shall govern for purposes of the
subject matter of this Amendment only. This Amendment is in English language, which, together with the English translation of the Agreement as filed with the U.S. Securities and Exchange Commission on January 19, 2007 on Form F-1, shall be the
official version for all purposes. 


     C. Severability. If any provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or other authority to be invalid, illegal or unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Amendment shall remain in full force and effect and shall in no way be effected, impaired or invalidated. 


     D. Governing Law. This Amendment shall be deemed to be a contract made under the laws of the People's Republic of China. and for all purposes shall be governed by and construed in accordance with such laws. 











Exhibit 4.21 


     F. Counterparts. This Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same
instrument. 


     G. Descriptive Headings. Descriptive headings appear herein for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof. 


     H. Effective Date of Amendment. This Amendment shall be deemed effective as December 31, 2012, as if executed on such date.. 


[Signature Page Follows on the Next Page] 



 



 











Exhibit 4.21 


PARTY A: SHENYANG SUNSHINE 

PHARMACEUTICAL COMPANY LIMITED 


By: /s/ Jing  Lou 

Name: Jing Lou 

Title: Chairman 


PARTY B: Mr. Dan LOU  


By:  /s/ Dan Lou 

Name: Dan Lou